Related Experiment Video
Updated: Aug 18, 2025
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Interactive webtool for analyzing drug sensitivity and resistance associated with genetic signatures of cancer cell
Myriam Boeschen1,2, Diana Le Duc3, Mathias Stiller4
1Rudolf Schönheimer Institute of Biochemistry, Medical Faculty, University of Leipzig, Johannisallee 30, 04103, Leipzig, Germany. Myriam.Boeschen@medizin.uni-leipzig.de.
Purpose:
A wide therapeutic repertoire has become available to oncologists including radio- and chemotherapy, small molecules and monoclonal antibodies. However, drug efficacy can be limited by genetic heterogeneity. Here, we designed a webtool that facilitates the data analysis of the in vitro drug sensitivity data on 265 approved compounds from the GDSC database in association with a plethora of genetic changes documented for 1001 cell lines in the CCLE data.
Methods:
The webtool computes odds ratios of drug resistance for a queried set of genetic alterations. It provides results on the efficacy of single compounds or groups of compounds assigned to cellular signaling pathways. Webtool availability: https://tools.hornlab.org/GDSC/ .
Results:
We first replicated established associations of genetic driver mutations in BRAF, RAS genes and EGFR with drug response. We then tested the 'BRCAness' hypothesis and did not find increased sensitivity to the assayed PARP inhibitors. Analyzing specific PIK3CA mutations related to cancer and mendelian overgrowth, we found support for the described sensitivity of H1047 mutants to GSK690693 targeting the AKT pathway. Testing a co-mutated gene pair, GATA3 activation abolished PTEN-related sensitivity to PI3K/mTOR inhibition. Finally, the pharmacogenomic modifier ABCB1 was associated with olaparib resistance.
Conclusions:
This tool could identify potential drug candidates in the presence of custom sets of genetic changes and moreover, improve the understanding of signaling pathways. The underlying computer code can be adapted to larger drug response datasets to help structure and accommodate the increasingly large biomedical knowledge base.
Insights
This study introduces a webtool for analyzing drug sensitivity data against genetic alterations in cancer cell lines. The tool helps identify potential drug candidates and understand signaling pathways, aiding personalized cancer therapy.
Area of Science:
- Pharmacogenomics
- Cancer Biology
- Computational Biology
Background:
- Cancer treatment faces challenges due to genetic heterogeneity, impacting drug efficacy.
- Large-scale pharmacogenomic datasets (GDSC, CCLE) offer opportunities to understand drug response.
- Developing tools to analyze these datasets is crucial for advancing precision oncology.
Purpose of the Study:
- To design and present a webtool for analyzing in vitro drug sensitivity data from the Genomics of Drug Sensitivity in Cancer (GDSC) database.
- To associate drug response with genetic alterations across 1001 cancer cell lines from the Cancer Cell Line Encyclopedia (CCLE).
- To facilitate the identification of potential drug candidates based on specific genetic profiles.
Main Methods:
- The webtool calculates odds ratios for drug resistance associated with queried genetic alterations.
- It analyzes the efficacy of individual compounds and compound groups targeting specific cellular signaling pathways.
- The tool integrates data from the GDSC and CCLE databases.
Main Results:
- Replication of known associations between mutations (BRAF, RAS, EGFR) and drug response.
- No increased sensitivity to PARP inhibitors was observed under the 'BRCAness' hypothesis.
- Support found for PIK3CA mutation (H1047) sensitivity to AKT pathway inhibitor GSK690693.
- GATA3 activation was found to abolish PTEN-related sensitivity to PI3K/mTOR inhibition.
- ABCB1 was associated with resistance to olaparib.
Conclusions:
- The developed tool can identify potential drug candidates for specific genetic alterations.
- It enhances the understanding of cellular signaling pathways in cancer drug response.
- The underlying computational framework is adaptable for larger datasets, supporting biomedical knowledge integration.
